FDA Panel Reviews First mRNA-Based Flu Vaccine Candidate
The U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee has begun reviewing a first-of-its-kind flu vaccine that utilizes messenger RNA (mRNA) technology.
mRNA vaccines work by instructing cells to produce proteins that trigger an immune response, teaching the body to recognize and fight specific pathogens. This approach gained widespread attention during the COVID-19 pandemic, and researchers have since been exploring its application to other diseases, including seasonal influenza.
If the panel recommends authorization and the FDA approves the vaccine, it would represent a notable expansion of mRNA technology beyond its initial pandemic-era applications. Traditional flu vaccines are typically produced using eggs or cell cultures, a process that can take several months. mRNA vaccines may offer advantages in manufacturing speed and potentially broader protection against evolving flu strains.
The advisory committee's review focuses on evaluating the vaccine's safety, efficacy, and manufacturing quality before a final decision is made.